● pepmg Research Desk · Peer-reviewed evidence review
What the research says about AOD-9604
A neutral summary of the peer-reviewed literature on AOD-9604, a C-terminal fragment of human growth hormone studied as a lipolytic anti-obesity candidate. The human evidence is older and limited, and much of the recent literature is anti-doping detection methodology rather than efficacy. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- AOD-9604 is a synthetic fragment of human growth hormone (the C-terminal lipolytic region) that was advanced as an anti-obesity candidate [3][7].
- Reviews describe a phase II obesity development program, but the primary controlled-trial evidence in this literature is older and limited, and much of the recent work is anti-doping detection methodology rather than efficacy [2][3][6][7].
- There is no large modern randomized trial of AOD-9604 in this corpus; its human safety and efficacy are not established [5][8].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What AOD-9604 is
AOD-9604 is described in the literature as a synthetic peptide corresponding to the C-terminal fragment of human growth hormone (amino acids 177-191) with an added tyrosine residue at the N-terminus, developed as an anti-obesity candidate [7]. It is reported to mimic the lipolytic (fat-metabolizing) properties of growth hormone without the diabetogenic effects attributed to the whole hormone [7]. It is sold by third-party research-chemical vendors and is offered for laboratory and research use only.
The compound was advanced through an industry obesity drug-development program: reviews of anti-obesity agents in clinical development describe AOD-9604 as a growth-hormone fragment that reached early-phase (phase II) trials [2][3][5]. The controlled-trial literature available here, however, is limited and dates largely to that development era, and much of the more recent published work concerns anti-doping detection methods rather than efficacy [6][7].
What the research has measured
Limited evidenceEarly mechanistic work examined AOD-9604 in animals. In a study in obese mice and beta-3-adrenergic-receptor knockout mice, both human growth hormone and AOD-9604 were reported to reduce body weight and body fat and to raise expression of the beta-3-adrenergic receptor, a lipolytic receptor found in fat cells; the authors concluded the lipolytic actions were not mediated directly through that receptor [1]. This is animal, mechanistic work, not a human efficacy trial.
Reviews of the obesity-drug pipeline list AOD-9604 among human-growth-hormone-fragment candidates in clinical development, describing a phase II program aimed at weight reduction [2][3][4][5]. These are narrative reviews summarizing development status rather than primary reports of controlled trials, and the primary controlled-trial evidence for efficacy is not represented in this corpus.
A substantial part of the recent AOD-9604 literature is analytical rather than clinical. Methods work developed assays to detect the peptide and its metabolites in urine and serum for anti-doping purposes [7], and a separate study reported that AOD-9604 does not interfere with the World Anti-Doping Agency growth-hormone isoform immunoassay [6]. This work characterizes detection and metabolism, not whether the compound produces a clinical benefit.
What the trials report on safety and adverse events
Limited evidenceThe controlled human safety data for AOD-9604 in this literature are limited. Reviews place it among growth-hormone-fragment candidates that entered early-phase obesity trials [2][3][5], but the corpus here does not contain a large controlled safety trial to summarize, and detailed adverse-event reporting is not available in these records.
A recent review of growth-hormone/IGF-1-axis peptides used outside medical supervision groups AOD-9604 among compounds whose reported adverse effects across this class span endocrine and metabolic disturbances, fluid retention, musculoskeletal symptoms, and injection-site reactions, while emphasizing the absence of regulatory approval and the uncertainty of unregulated product composition [8]. Because large controlled trials are lacking, the human safety of AOD-9604 is not established. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
AOD-9604 has an older, thin human evidence base: a clinical-development program that reviews describe as having reached early-phase obesity trials, mechanistic animal work, and a more recent body of anti-doping detection methodology [2][5][6][7]. The corpus here does not contain a large modern randomized controlled trial establishing efficacy, so the evidence is characterized as limited [2][7]. "Limited" describes the state of the research, not a judgment of whether AOD-9604 works or is safe.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 8
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
- AOD-9604 Metabolic.
- Obesity drugs in clinical development.
- Current updates in the medical management of obesity.
- [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
- AOD-9604 does not influence the WADA hGH isoform immunoassay.
- Detection and in vitro metabolism of AOD9604.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.